Solution

////////////////

1. Human-Relevant Validation: From Tumoroid to Trial-on-Chip

3D Patient-Derived Tumoroids: Mini-tumors grown from patient biopsies that capture genetic diversity and the tumor microenvironment; show approximately 80–88% concordance with patient outcomes.

Ex Vivo Organotypic Slices: Fresh tissue slices that preserve vasculature, stroma, and immune context, offering over 80% predictive accuracy for therapy response.

Microfluidic Lab-on-Chip Systems: Miniaturized platforms that recreate organ-level functions and inter-organ communication under controlled flow, enabling simultaneous evaluation of efficacy, toxicity, and pharmacokinetics in human-cell-based systems.

Trial-on-Chip Modules: Integrated multi-organ microphysiological networks representing “virtual clinical trials in a chip.” These allow parallel testing of drug candidates across patient-derived tumoroids, liver, and immune compartments—bridging preclinical discovery to first-in-human design with unmatched translational fidelity.

2. Relevant AI model and Human Biology

Predictive Intelligence

Integrating multi-omic, pharmacogenomic, and clinical data to identify optimal targets,pathways, combinations, biomarkers and patient responders—eliminating guesswork and prioritizing programs with maximal biological validity.

Generative AI

Trained on large curated chemical, bioactivity, and omics datasets, AI learns the “chemical grammar” and structure–activity rules that drive New compounds development. Some core components include: Generative chemistry (SMILES / graph diffusion models) for de-novo molecule creation. Predictive ADMET filters to eliminate toxic or off-target scaffolds. Multi-omic embeddings linking compounds to phenotypic signatures. Reinforcement learning guided by experimental feedback from wet lab (3D tumoroids, ex vivo slices, and lab-on-chip assays).

Through this closed loop, AI continuously designs, optimizes, and prioritizes new molecula entities grounded in human-relevant data.

Together, these powerful AI engine can do prediction and generation to power precision drug discovery.

3. Automation & Data Integration Layer

Bringing in automation connects high-throughput robotics, microfluidics, imaging, assay dispensing and analytics systems to run thousands of assays per week with precision and traceability. Automation captures every data point into a unified data lake, where AI continuously retrains on new results-turning months of manual work into days and creating a self-learning, self-optimizing discovery ecosystem. For example, testing a drug candidate on a dozen different tumoroid lines under various dosing regimens would be very time- and labor-intensive to do manually. But with automated liquid handlers, plate loaders, and high-content imaging systems, we can run many such experiments in parallel and collect data rapidly.Automation also improves precision and reproducibility by minimizing human error and variability. By scaling up via automation, we can explore more compounds and more tumor models than a typical lab, which increases the chances of finding effective drug–target pairs and allows optimization of lead compounds much faster . This directly tackles the timeline issue: it enables a design → test → learn → redesign iteration loop that moves at Silicon Valley speed instead of traditional pharma speed. As peers like Recursion , Gingko Bioworks have shown, integrating automation and AI creates a virtuous cycle of rapid hypothesis generation and validation . This high-speed cycling is crucial to outpacing cancer and staying nimble when data suggests a change in direction.

4. Quantified Impact

(Sources: Deloitte 2024; Vlachogiannis et al., Science 2018; Leavitt et al., Nat Med 2023; Katamaran benchmarks.)

The Vision Ahead

“Design, generate, and test directly on human biology from day one.”

By coupling Ai’s predictive intelligence, generation, automated execution, directly with human relevant translational modeling, We can convert drug discovery from a high-risk art into a reproducible, data-driven science accelerating cures across oncology, neurodegeneration, and rare diseases.

The Vision Ahead

“Design, generate, and test directly on human biology from day one.”

By coupling Ai’s predictive intelligence, generation, automated execution, directly with human relevant translational modeling, We can convert drug discovery from a high-risk art into a reproducible, data-driven science—accelerating cures across oncology, neurodegeneration, and rare diseases.

We’re looking for collaborators, investors, and visionary scientists. Reach out and be part of the mission.